These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37236514)

  • 21. Effect of methotrexate hold on COVID-19 vaccine response in the patients with autoimmune inflammatory disorders: a systematic review and meta-analysis.
    Imran M; Ali S; Ibrahim AA; Amjad A; Tanveer A; Khalil S; Ali M; Abuelazm M
    Clin Rheumatol; 2024 Jul; 43(7):2203-2214. PubMed ID: 38802670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study.
    Tut G; Lancaster T; Sylla P; Butler MS; Kaur N; Spalkova E; Bentley C; Amin U; Jadir A; Hulme S; Ayodele M; Bone D; Tut E; Bruton R; Krutikov M; Giddings R; Shrotri M; Azmi B; Fuller C; Baynton V; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
    Lancet Healthy Longev; 2022 Jul; 3(7):e461-e469. PubMed ID: 35813280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
    Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
    Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases.
    Dayam RM; Law JC; Goetgebuer RL; Chao GY; Abe KT; Sutton M; Finkelstein N; Stempak JM; Pereira D; Croitoru D; Acheampong L; Rizwan S; Rymaszewski K; Milgrom R; Ganatra D; Batista NV; Girard M; Lau I; Law R; Cheung MW; Rathod B; Kitaygorodsky J; Samson R; Hu Q; Hardy WR; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Gingras AC; Watts TH
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35471956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
    Syversen SW; Jyssum I; Tveter AT; Sexton J; Christensen IE; Tran TT; Bjørlykke KH; Mjaaland S; Warren DJ; Kvien TK; Chopra A; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Grødeland G; Vaage JT; Provan SA; Jørgensen KK; Goll GL
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).
    Tran AP; Tassone D; Nossent J; Ding NS
    RMD Open; 2022 May; 8(1):. PubMed ID: 35577478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.
    Kartnig F; Mrak D; Simader E; Tobudic S; Radner H; Mandl P; Göschl L; Hommer N; Mayer M; Hofer P; Hummel T; Deimel T; Geßl I; Puchner A; Kerschbaumer A; Thalhammer R; Handisurya A; Kain R; Winkler S; Smolen JS; Stiasny K; Perkmann T; Haslacher H; Aberle JH; Aletaha D; Heinz LX; Sieghart D; Bonelli M
    Ann Rheum Dis; 2023 Feb; 82(2):292-300. PubMed ID: 36109141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study.
    Kvist-Hansen A; Pérez-Alós L; Al-Sofi RF; Heftdal LD; Hamm SR; Møller DL; Pries-Heje MM; Fogh K; Hansen CB; Hasselbalch RB; Madsen JR; Armenteros JJA; Frikke-Schmidt R; Hilsted L; Sørensen E; Ostrowski SR; Bundgaard H; Nielsen SD; Iversen K; Zachariae C; Garred P; Skov L
    Br J Dermatol; 2023 Apr; 188(5):661-669. PubMed ID: 36703193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.
    Habermann E; Gieselmann L; Tober-Lau P; Klotsche J; Albach FN; Ten Hagen A; Zernicke J; Ahmadov E; Arumahandi de Silva AN; Frommert LM; Kurth F; Sander LE; Burmester GR; Klein F; Biesen R
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
    Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
    Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
    Abhishek A; Peckham N; Pade C; Gibbons JM; Cureton L; Francis A; Barber V; Williams JAE; Appelbe D; Eldridge L; Julier P; Altmann DM; Bluett J; Brooks T; Coates LC; Rombach I; Semper A; Otter A; Valdes AM; Nguyen-Van-Tam JS; Williams HC; Boyton RJ; McKnight Á; Cook JA;
    Lancet Rheumatol; 2024 Feb; 6(2):e92-e104. PubMed ID: 38267107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity.
    Erra L; Uriarte I; Colado A; Paolini MV; Seminario G; Fernández JB; Tau L; Bernatowiez J; Moreira I; Vishnopolska S; Rumbo M; Cassarino C; Vijoditz G; López AL; Curciarello R; Rodríguez D; Rizzo G; Ferreyra M; Ferreyra Mufarregue LR; Badano MN; Pérez Millán MI; Quiroga MF; Baré P; Ibañez I; Pozner R; Borge M; Docena G; Bezrodnik L; Almejun MB
    J Clin Immunol; 2023 Feb; 43(2):271-285. PubMed ID: 36251205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
    Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
    Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
    Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
    J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
    Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
    Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
    Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
    J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.